Healthcare Long/Short Equity
Fundamental, science-driven long/short equity strategy focused on providing exposure to specific disease indications through investments in biopharma companies
StemPoint Capital (“StemPoint”) is a long-biased, biopharma focused, long/short equity strategy. StemPoint seeks to employ a fundamental, science-driven research process focused on providing exposure to sector themes and specific disease indications through investments in large-cap biopharmaceutical companies and small/mid-cap biotechnology companies.